None listed
Conditions
Brief summary
This study will focus on patients who are planned for surgical resection of the oesophagus or stomach as part of curative treatment for oesophageal, oesophagogastric junction (OGJ) or gastric (stomach) cancer. Oesophagogastric (OG) cancer surgery is associated with significant morbidity with specific challenges related to consuming enough food and fluids, poor nutrition status, reduced physical performance and impaired health related quality of life (QOL). Malnutrition and low muscularity (or low muscle mass) is common in patients with gastrointestinal cancer regardless of body weight or body mass index (BMI). Routine diagnostic computed tomography (CT) images can be used to assess body composition and have shown that low muscularity prior to surgery can lead to increased hospital length of stay, postoperative complications, mortality and reduced overall survival after gastrointestinal cancer surgery. Sarcopenia, commonly used to describe age related loss of skeletal muscle mass with low muscle strength and/or low physical performance, is also associated with poor health related outcomes but is yet to be explored in the context of the surgical oncology population. This prospective observational pilot study aims understand the clinical, nutritional and functional differences between sarcopenic and non-sarcopenic patients undergoing surgical treatment for oesophagogastric carcinoma, thereby defining two distinct syndromes. In addition, we aim to assess changes in the specific components of sarcopenia after OG cancer surgery and the influence on postoperative recovery. As a pilot study we aim to identify areas of potential difference between these sarcopenic and non-sarcopenic groups that may account for differences in treatment outcomes and lead to future larger scale research endeavours that consider specific interventions to prevent or reduce the development of sarcopenia.
Interventions
Condition observed 1. Malnutrition: baseline (before surgery) and 2 weeks, 6 weeks, 12 weeks, 6 months, and 12 months postoperatively. Assessment of malnutrition includes measuring body weight, body mass index (BMI), weight loss, muscle mass and dietary intake (3-day food diary). Muscle mass will be assessed using computed tomography (CT) when the images are taken at 3 time points for routine clinical purposes (initial diagnosis, preoperative restaging, and 12-month surveillance). Bioelectrical impedance spectroscopy (BIS) will also be used to measure muscle mass before surgery, and 2 weeks, 6 weeks, 12 weeks, 6 months, and 12 months after surgery. 2. Sarcopenia: baseline (before surgery) and 2 weeks, 6 weeks, 12 weeks, 6 months, and 12 months postoperatively. Sarcopenia diagnosis includes assessment of muscle strength (hand-grip strength dynamometer), muscle mass (CT or BIS body composition assessment), muscle quality or density (CT body composition assessment), and physical function (6-meter walk test). 3. Quality of life (QOL): baseline (before surgery) and 2 weeks, 6 weeks, 12 weeks, 6 months, and 12 months postoperatively. Assessed using the European Organisation for Research Treatment of Cancer (EORTC) quality of life questionnaire (QLQ-C30, version 3) and the oesophagogastric cancer specific module (EORTC QLQ-OG25). Additional information regarding the assessment of the above-mentioned conditions: 1. CT body composition analysis. The CT image used to assess body composition is those taken for routine clinical purposes at initial diagnosis, for restaging after chemotherapy and/or radiotherapy (this time point is before surgery) and at 12 months after surgery. This will take approximately 30-40 minutes to analyze the scan and obtain the results. Assessment of the CT image is done outside of the participant contact time. The CT body composition assessment is completed by a trained and competent dietitian, with supervision and assistance from a radiologist as required. A second trained dietitian will assess 10% of the CT images to determine inter-rater reliability. 2. Sarcopenia diagnosis. The three measurements required to diagnose sarcopenia are muscle mass (fat-free mass index using bioimpedance spectroscopy (BIS)), muscle strength (using hand-grip strength dynamometer), and physical function (using a 6-meter timed walk test). At each time point, these assessments will be carried out by a dietitian who is trained to operate and interpret the results from the BIS machine (no supervision is required). The assessments will take place in the surgical outpatient clinic rooms at Alfred Hospital. We anticipate that it may take up to 30 minutes to complete these assessments. 3. Questionnaires. The QOL surveys and 3-day food diaries are intended to be completed by the participant prior to their study appointment. On the occasion where the survey has not been completed, we estimate that it may take 15-20 minutes for the dietitian to complete them with the patient. Supervision is not required. Completion of the questionnaires will take place in the surgical outpatient clinic at The Alfred Hospital. Exposure Potentially curative surgical resection of oesophageal, gastric, or oesophagogastric junction cancer.
Sponsors
Eligibility
Inclusion criteria
Adults greater than or equal to 18 years of age. Diagnosis of an oesophageal, oesophagogastric junction, or gastric carcinoma. Eligible for oesophagectomy, total gastrectomy or total extended gastrectomy, partial gastrectomy, or distal gastrectomy with curative intent. Must be a patient of the Alfred Health Upper Gastrointestinal Surgery unit with multimodal treatment options discussed at The Alfred UGIS oncology multidisciplinary meeting.
Exclusion criteria
• Patients less than 18 years of age • Resection of the oesophagus or stomach for reasons other than carcinoma resection • Planned for a palliative surgical procedure Resection of benign cancers, e.g. gastrointestinal stromal tumours (GIST) Ineligible to undergo BIS assessment due to BMI greater than or equal to 35kg/m2, patients with clinical signs of oedema, patients with endocrine diseases that influence body composition (e.g. Cushing syndrome), patients who have a pacemaker or an electronic implantable device, or patients treated with growth hormone. NOTE: these patients will only be excluded from the BIS component of the study, their CT images can still be obtained to assess body composition. Patients who do not wish to have their medical follow-up at The Alfred Hospital and who are not willing to come to the Alfred for research purposes only Patients who are unable to comply with the requirements of the study due to cognitive impairment